Actively Recruiting
Analysis of Biomarkers From Patients With Chorioretinal Diseases
Led by Kyungpook National University Hospital · Updated on 2025-03-06
100
Participants Needed
1
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with various chorioretinal diseases such as diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (both dry and wet types), and retinal degeneration. The goal is to investigate levels of ocular biomarkers in these patients compared to control patients without diabetic retinopathy undergoing cataract or other eye surgeries. This observational study aims to better understand biomarker changes related to these eye conditions. The study includes two groups: patients with chorioretinal diseases and control patients who are undergoing surgeries like cataract removal or vitrectomy for other eye issues. Before treatment with anti-vascular endothelial growth factor agents or other retinal surgeries, ocular fluid and blood samples are collected from participants. These samples are then analyzed to measure ocular biomarkers. Participants will have samples taken before their eye treatments and will be monitored for biomarker levels, with a primary outcome measured one month after sampling. The study involves 50 patients in each group, with assessments including ocular fluid and blood sample analysis. Participation involves routine ophthalmologic evaluations and sample collections. The overall study duration spans from initial sample collection to biomarker analysis at one month post-procedure.
CONDITIONS
Brief Title
Analysis of Biomarkers From Patients With Chorioretinal Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 20 years
- Patients needing ophthalmologic treatment for decreased visual acuity
- Patients with chorioretinal diseases such as diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration
- Control patients scheduled for cataract surgery or vitrectomy for nonproliferative posterior segment disorders
You will not qualify if you...
- Under 20 years of age
- Patients who received anti-vascular endothelial growth factor treatment for proliferative disease before aqueous humor sampling
- Patients who did not sign informed consent
- Patients with intraocular inflammation or infection requiring treatment
- Patients with recent ocular trauma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 day
Participants undergo ocular fluid and blood sample collection before receiving treatment or surgery.
1 visit (in-person)
Duration - 1 month
Participants are followed for analysis of biomarkers in ocular fluids over one month after treatment or surgery.
1 follow-up visit
Trial Site Locations
Total: 1 location
1
Dong Ho Park
Daegu, Kyungsangpookdo, South Korea, 700-721
Actively Recruiting
Research Team
D
Dong Ho Park, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here